U.S. markets open in 4 hours 48 minutes
  • S&P Futures

    4,293.50
    -14.25 (-0.33%)
     
  • Dow Futures

    34,047.00
    -71.00 (-0.21%)
     
  • Nasdaq Futures

    13,592.25
    -66.00 (-0.48%)
     
  • Russell 2000 Futures

    2,017.50
    -5.80 (-0.29%)
     
  • Crude Oil

    86.25
    -0.28 (-0.32%)
     
  • Gold

    1,789.60
    -0.10 (-0.01%)
     
  • Silver

    19.98
    -0.11 (-0.55%)
     
  • EUR/USD

    1.0184
    +0.0013 (+0.13%)
     
  • 10-Yr Bond

    2.8240
    0.0000 (0.00%)
     
  • Vix

    19.95
    0.00 (0.00%)
     
  • GBP/USD

    1.2108
    +0.0013 (+0.11%)
     
  • USD/JPY

    134.7560
    +0.5410 (+0.40%)
     
  • BTC-USD

    23,826.22
    -190.07 (-0.79%)
     
  • CMC Crypto 200

    568.81
    -3.11 (-0.54%)
     
  • FTSE 100

    7,530.92
    -5.14 (-0.07%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

Geron to Announce Second Quarter 2022 Financial Results on August 11, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

FOSTER CITY, Calif., August 04, 2022--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 11, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as key upcoming expected milestones at 4:30 p.m. ET the same day.

A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.

Participants may access the webcast by registering online using the following link, https://conferencingportals.com/event/SmvlMvWL. Participants that are unable to register online can access the conference call via telephone by dialing domestically +1 (888) 330-2434 or internationally +1 (240) 789-2725. The conference ID is 67335.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005001/en/

Contacts

Aron Feingold
Investor and Media Relations
investor@geron.com
media@geron.com